CN1905875B - 吡啶*盐作为血管保护剂的用途 - Google Patents

吡啶*盐作为血管保护剂的用途 Download PDF

Info

Publication number
CN1905875B
CN1905875B CN2005800017124A CN200580001712A CN1905875B CN 1905875 B CN1905875 B CN 1905875B CN 2005800017124 A CN2005800017124 A CN 2005800017124A CN 200580001712 A CN200580001712 A CN 200580001712A CN 1905875 B CN1905875 B CN 1905875B
Authority
CN
China
Prior art keywords
disease
purposes
chronic
blood vessel
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800017124A
Other languages
English (en)
Chinese (zh)
Other versions
CN1905875A (zh
Inventor
J·戈比克
S·驰罗匹克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmena SA
Original Assignee
Pharmena SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmena SA filed Critical Pharmena SA
Publication of CN1905875A publication Critical patent/CN1905875A/zh
Application granted granted Critical
Publication of CN1905875B publication Critical patent/CN1905875B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
CN2005800017124A 2004-01-12 2005-01-07 吡啶*盐作为血管保护剂的用途 Expired - Lifetime CN1905875B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PL04364348A PL364348A1 (en) 2004-01-12 2004-01-12 Application of quaternary pyridine salts as vessel protection agent
PLP-364348 2004-01-12
PLP364348 2004-01-12
PCT/EP2005/050057 WO2005067927A2 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents

Publications (2)

Publication Number Publication Date
CN1905875A CN1905875A (zh) 2007-01-31
CN1905875B true CN1905875B (zh) 2010-07-28

Family

ID=34793495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800017124A Expired - Lifetime CN1905875B (zh) 2004-01-12 2005-01-07 吡啶*盐作为血管保护剂的用途

Country Status (13)

Country Link
US (6) US7935717B2 (https=)
EP (2) EP2279738A1 (https=)
JP (2) JP5052138B2 (https=)
CN (1) CN1905875B (https=)
AT (1) ATE524179T1 (https=)
AU (1) AU2005205066C1 (https=)
CA (1) CA2547234C (https=)
DK (1) DK1713480T3 (https=)
ES (1) ES2372756T3 (https=)
PL (2) PL364348A1 (https=)
PT (1) PT1713480E (https=)
RU (1) RU2366420C2 (https=)
WO (1) WO2005067927A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
EP1963270B1 (en) * 2005-12-09 2009-08-05 Cerecon AG Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
PT2026651E (pt) 2006-03-08 2013-06-04 Cortria Corp Terapia combinada com inibidores cox não selectivos para prevenir lesões gástricas relacionadas com a cox
JP2010506900A (ja) * 2006-10-18 2010-03-04 デルメナ リポ蛋白質異常症並びに皮膚疾病および皮膚障害の処置のためのｎ−メチルニコチンアミドを含有する食品抽出物
PL381862A1 (pl) * 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
US20090118225A1 (en) * 2007-09-28 2009-05-07 Cortria Corporation 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury
EP2211857B1 (en) * 2007-10-12 2012-09-12 Politechnika Lodzka Use of quaternary pyridinium salts for radioprotection
US8304439B1 (en) 2007-10-12 2012-11-06 Politechnika Lodzka Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
PL2211858T3 (pl) 2007-10-12 2015-06-30 Politechnika Lodzka Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych
EP2285379A4 (en) * 2008-05-06 2011-11-02 Cortria Corp ANALOGUES OF 1-METHYLNICOTINAMIDE
CA2764739A1 (en) * 2008-07-01 2010-01-07 Politechnika Lodzka N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
RU2425672C1 (ru) * 2010-04-12 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипергомоцистеин-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200
KR101309576B1 (ko) * 2011-05-25 2013-09-17 연세대학교 산학협력단 대사물질을 이용한 심부전 바이오마커
PL226999B1 (pl) * 2013-06-11 2017-10-31 Univ Jagiellonski Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie
CN105771005A (zh) * 2016-03-24 2016-07-20 乐普（北京）医疗器械股份有限公司 一种抗风湿性血管狭窄药物支架及其制备方法和应用
WO2018015862A1 (en) 2016-07-18 2018-01-25 Pharmena S.A. 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
DK3484475T3 (da) * 2016-07-18 2023-11-27 Pharmena S A 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
ES2998765T3 (en) * 2017-07-27 2025-02-21 Univ Michigan Regents Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use
PL238932B1 (pl) * 2017-12-31 2021-10-18 Univ Jagiellonski Pochodne soli pirydyniowych oraz ich zastosowanie
US10864207B2 (en) * 2019-01-02 2020-12-15 Celagenex Research (India) Pvt. Ltd. Method of treating endothelial dysfunction
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
WO2022061234A2 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Immunological effects of metabolites
CN115837023B (zh) * 2023-02-20 2023-05-16 中山大学附属第八医院（深圳福田） 1-甲基烟酰胺在制备抗血管钙化药物中的应用
PL248942B1 (pl) * 2024-01-31 2026-02-16 Politechnika Poznanska Czwartorzędowe sole amoniowe zawierające anion 2-furanokarboksylanowy i kation będący alkilową pochodną nikotynamidu, sposób ich otrzymywania i zastosowanie jako środki myjąco-dezynfekujące
PL447656A1 (pl) * 2024-01-31 2025-08-04 Politechnika Poznańska Nowe czwartorzędowe sole amoniowe zawierające anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL449092A1 (pl) * 2024-07-01 2026-01-05 Uniwersytet Jagielloński Synergiczna kombinacja 1-metylonikotynamidu (MNA) i witaminy K do zastosowania w leczeniu lub zapobieganiu powikłaniom sercowo-naczyniowym terapii przeciwnowotworowych

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040559A1 (en) * 1999-01-07 2000-07-13 Technical University Of Lodz Compositions for the treatment of skin diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
DE840698C (de) * 1949-07-12 1952-06-05 Cilag Aktiengesellschaft Verfahren zur herstellung neuer derivate des nicotinsaureamids
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20060263428A1 (en) 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6406715B1 (en) 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20030157153A1 (en) 1997-03-06 2003-08-21 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
IE970731A1 (en) 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
JP2002255846A (ja) * 2001-02-26 2002-09-11 Sunstar Inc 経口組成物
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
CN101076331A (zh) 2004-11-05 2007-11-21 艾尼纳制药公司 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
JP2010506900A (ja) * 2006-10-18 2010-03-04 デルメナ リポ蛋白質異常症並びに皮膚疾病および皮膚障害の処置のためのｎ−メチルニコチンアミドを含有する食品抽出物
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040559A1 (en) * 1999-01-07 2000-07-13 Technical University Of Lodz Compositions for the treatment of skin diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FILETTI, S. ET AL.Insulin receptor down-regulation prevention at a postreceptorsite.ENDOCRINOLOGY108 6.1981,108(6),2409-11.
FILETTI,S.ET AL.Insulin receptor down-regulation prevention at a postreceptorsite.ENDOCRINOLOGY108 6.1981,108(6),2409-11. *
FUKUSHIMA T ET AL.RADICAL FORMATION SITE OF CEREBRAL COMPLEXIAND PARKINSON＇S DISEASE.JOURNAL OF NEUROSCIENCE RESERRCH42.1995,42385-390. *
FUKUSHIMA,TETSUHITO et al.Possible role of 1-methylnicotinamide in thepathogenesisofParkinson＇s disease.Experimental and Toxicolog Pathology53 6.2002,53(6),469-473.
FUKUSHIMA,TETSUHITO et al.Possible role of 1-methylnicotinamide in thepathogenesisofParkinson＇s disease.Experimental and Toxicolog Pathology53 6.2002,53(6),469-473. *
Jerzy et al.1-METHYLNICOTINAMIDE: APOTENTANTI-INELAMMATORY AGENT OF VITAMINORIGIN.Polish Journal of Pharmacology55.2003,55109-112. *
LEA MA ET AL.EFFECTS OF NICOTINAMIDE AND STRUCTURALANALOGS ON DAN SYNTHESIS AND CELLULARPERLICATION OF RAT HEPATOMA CELLS.CANCER BIOCHEMISTRY BIOPHYSICS, GORDON AND BREACH SCIENCE PUBLISHER7 3.1984,7(3),195-202.
LEA MA ET AL.EFFECTS OF NICOTINAMIDE AND STRUCTURALANALOGS ON DAN SYNTHESIS AND CELLULARPERLICATION OF RAT HEPATOMA CELLS.CANCER BIOCHEMISTRY BIOPHYSICS, GORDON AND BREACH SCIENCE PUBLISHER7 3.1984,7(3),195-202. *

Also Published As

Publication number Publication date
RU2006129299A (ru) 2008-02-20
US8969391B2 (en) 2015-03-03
WO2005067927A3 (en) 2005-12-01
ATE524179T1 (de) 2011-09-15
JP5597179B2 (ja) 2014-10-01
JP5052138B2 (ja) 2012-10-17
RU2366420C2 (ru) 2009-09-10
US9119844B2 (en) 2015-09-01
AU2005205066B2 (en) 2010-04-29
CA2547234C (en) 2010-07-20
EP1713480A2 (en) 2006-10-25
AU2005205066C1 (en) 2010-08-26
US7935717B2 (en) 2011-05-03
US9333196B2 (en) 2016-05-10
US20140296305A1 (en) 2014-10-02
US20080207702A1 (en) 2008-08-28
DK1713480T3 (da) 2012-01-16
JP2007517833A (ja) 2007-07-05
PL364348A1 (en) 2005-07-25
PL1713480T3 (pl) 2011-12-30
US20110245297A1 (en) 2011-10-06
US20100173956A1 (en) 2010-07-08
EP2279738A1 (en) 2011-02-02
CN1905875A (zh) 2007-01-31
US20160346265A1 (en) 2016-12-01
CA2547234A1 (en) 2005-07-28
US9675601B2 (en) 2017-06-13
US8124631B2 (en) 2012-02-28
ES2372756T3 (es) 2012-01-26
US20150133508A1 (en) 2015-05-14
EP1713480B1 (en) 2011-09-14
AU2005205066A1 (en) 2005-07-28
PT1713480E (pt) 2011-11-28
JP2012072150A (ja) 2012-04-12
WO2005067927A2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
CN1905875B (zh) 吡啶*盐作为血管保护剂的用途
CN100421659C (zh) 用于降低血浆脂蛋白(a)和心血管疾病危险因素的组合物和其制药用途
US7893095B2 (en) Use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
CN105792833A (zh) 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物
Rosenkranz et al. Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man.
US20180140579A1 (en) Sacubitril and valsartan for treating metabolic disease
Schram et al. The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial
MXPA06007930A (en) The use of quaternary pyridinium salts as vasoprotective agents
Kenny et al. Beneficial effects of diltiazem in coronary artery disease.
Fleischmann et al. Hypercholesterolaemia and treatment with statins do not alter l‐arginine‐induced changes of renal haemodynamics
KR20060061399A (ko) 항혈전제와 항혈소판 응집제로 구성된 결합체
Ito et al. Disposition of single-dose intravenous and oral aspirin in children
JPS6396124A (ja) アニパミル含有医薬
HK1130686B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20100728

CX01 Expiry of patent term